000			03068nam a22003855i 4500
001			298477
003			MX-SnUAN
005			20160429155506.0
007			cr nn 008mamaa
008			150903s2011 gw | o |||| 0|eng d
020			_a9783540857723 _99783540857723
024	7		_a10.1007/9783540857723 _2doi
035			_avtls000352119
039		9	_a201509030934 _bVLOAD _c201405060301 _dVLOAD _y201402171153 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC254-282
100	1		_aMoehler, Thomas. _eeditor. _9334882
245	1	0	_aMultiple Myeloma / _cedited by Thomas Moehler, Hartmut Goldschmidt.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2011.
300			_axxiv, 340 páginas _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aRecent Results in Cancer Research, _x0080-0015 ; _v183
500			_aSpringer eBooks
505	0		_aHistory and epidemiology -- Pathophysiology: Molecular biology of plasma cell disorders. Alterations in microenvironment -- Clinical Features: Imaging. Integrated innovative approach for diagnosis and staging -- Therapy: High-dose chemotherapy and ABSCT -- Allogeneic transplantation. Novel Drugs -- Immunotherapeutic approaches -- First-line treatment and maintenance -- Relapse -- Radiotherapy -- Kyphoplasty -- Supportive Therapy -- Appendix: Staging and prognosis systems.
520			_aMultiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy. In particular, the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide means that multiple myeloma now stands at the forefront of advances in oncology drug development. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aGoldschmidt, Hartmut. _eeditor. _9334883
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783540857716
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-540-85772-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c298477 _d298477